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pen accessAbstract Objectives: Evaluating the diagnostic and/or prognostic yield of serum levels of three
neuromarkers, serum S100 protein, neuron-speciﬁc enolase (NSE) and Glial Fibrillary Acidic Pro-
tein (GFAP), in patients who were admitted to surgical intensive care unit (SICU) and had closed
traumatic brain injury with suspicious presence of intracranial hematoma compared versus cranial
CT (CCT) as a gold standard diagnostic modality.
Patients and methods: The study included 70 patients who had sustained a closed traumatic brain
injury (TBI) requiring intensive care and/or surgical interference. All patients underwent clinical
evaluation for all traumatized organs using Injury Severity Score (ISS) and concerning TBI Glas-
gow Coma Scale (GCS) score was recorded after non-surgical resuscitation. Then, all underwent
CT scanning of the brain and patients with a surgically treatable mass underwent decompressive
craniotomy, while patients free of hematoma or with minute-to-small hematoma not necessitating
surgical interference were kept under observation. Venous blood samples were obtained from all
enrolled patients at time of admission and patients who showed deterioration during conservative
treatment gave second sample for ELISA estimation of serum S100 protein, NSE and GFAP.
Results: Forty-three patients had intracranial hematoma (Positive CCT); 26 patients underwent
surgical interference, while the other 17 hematoma patients and 27 hematoma free patients (Nega-
tive CCT) were kept under observation. Of them 15 patients; 10 with hematoma and ﬁve who were.com (H.A. Shehab).
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268 H.A. Shehab, Y.H. Nassarhematoma free developed symptoms of increased ICP and follow-up CCT examination deﬁned ﬁve
cases required surgical interference with 66.7% rate for unnecessary follow-up CCT. Thirty-nine
patients (55.7%) responded to conservative treatment and were discharged to the ward, while a
total of 31 patients (44.3%) had surgical interference. Mean serum levels of studied parameters were
signiﬁcantly higher in all patients compared to controls with signiﬁcantly higher levels in patients
who had positive CCT compared to those who had negative CCT and in patients who required sur-
gical interference compared to those managed conservatively. Patients who showed deterioration
had signiﬁcantly 2nd sample higher serum levels of S100 protein and GFAP, but non-signiﬁcantly
higher serum NSE levels compared to at admission levels. Percentage of increase of serum GFAP
levels in follow-up sample obtained from patients who had positive CCT was signiﬁcantly higher
compared to the percentage of increase in serum S100 protein and NSE.
Conclusion: Estimation of serum levels of neuromarkers as adjuvant diagnostic and prognostic
tools for closed TBI patients, but serum level of GFAP showed superior applicability and was more
valid prognostic modality that could spare unnecessary CCT if applied as the percentage of change
in comparison to at admission levels.
ª 2010 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
At a surgical intensive care unit, the diagnosis, treatment, and
prediction of outcome in traumatic brain injury present signif-
icant challenges to the treating clinician especially whenever,
traumatic brain injury was a part of multiple trauma or asso-
ciated with impaired or lost consciousness. Moreover, the neu-
rological status can sometimes be difﬁcult to evaluate because
of sedation and despite radiology provides important informa-
tion, but repeated investigations may not be feasible in criti-
cally ill patients [1–3].
However, clinical and radiological tools for assessing injury
severity and predicting outcome, in particular, lack sensitivity
and speciﬁcity. In patients with mild TBI, often there is uncer-
tainty about which patients should undergo radiological imag-
ing and who is at risk for long term neurological sequelae. In
severe TBI, often there is uncertainty about which patients will
experience secondary insults and what the outcome for individ-
ual patients will be [4,5].
These data point to the necessity for additional diagnostic
and/or prognostic modalities to be combined with clinical
and radiological data for evaluation and follow-up of patients
especially in the extremes of traumatic closed brain injury; the
mild that may be discharged home prior to manifesting full
picture and the severe that could not cope with the need for
frequent evaluation, and wherever CCT was not available.
Protein S100 is a dimeric acidic calcium-binding protein
with a molecular mass of 10–12 kD and a biological half-life
of about 1 h. It constitutes a major component of the cytosol
of various cell types, but protein S100B is predominantly pres-
ent in astrocytes and Schwann cells and can be both actively
secreted into the extracellular space and passively released by
cell death and the appearance of S100B in serum indicates both
neuronal damage and increased permeability of the blood–
brain barrier [6–8].
Enolase is a glycolytic enzyme that converts 2-phospho-D-
glycerate to phosphoenolpyruvate, has a molecular weight of
70 kD and a biological half-life of 48 h. The encephalic NSE
concentration ranges from 0.4% to 2.2%, and higher concen-
trations of NSE are found in the gray matter (e.g., neocortex)
and lower levels in the white matter (e.g., pyramidal tract and
corpus callosum). Besides being expressed selectively in neu-
rons, NSE has a high stability in biological ﬂuids and, as a freesoluble cytoplasmic protein, can easily diffuse to the extracel-
lular medium and cerebrospinal ﬂuid (CSF) when neuronal
membranes are injured [9–11].
The astrocytic Glial Fibrillary Acidic Protein (GFAP) is the
principal intermediate ﬁlament protein found in the cytoskele-
ton of mature astroglia [12]. Previous studies showed a delayed
release of the GFAP into the serum in patients with ischemic
stroke, reaching maximum concentrations between days 2
and 4. Because of the more sudden disruption of the blood–
brain barrier and the resulting brain damage, so it is hypothe-
sised that GFAP would immediately be detectable in serum in
the hyperacute phase of ICH [13–15].
Serum biomarkers were widely applicable for evaluation of
patients who had various forms of acute illness especially those
with misleading clinical and inconclusive radiological ﬁndings
and for prognosis of patients with severe illness [16,17]. It is
therefore imperative that inclusion of estimation of serum
markers as a part of ICU workup could aid early diagnosis
and adjustment of therapeutic planes for patients with closed
traumatic brain injury and may greatly improve outcome.
The present study aimed at evaluating the diagnostic and/or
prognostic yield of serum levels of three neuromarkers in pa-
tients admitted to SICU and had closed traumatic brain injury
with suspicious presence of intracranial hematoma compared
versus cranial CT as a gold standard diagnostic modality.
2. Patients and methods
The present prospective double-blinded study was conducted
at Departments of Anaesthesia and ICU, Neurosurgery Kasr
AL-Eini Hospital in conjunction with Medical Biochemistry
Department, Faculty of Medicine, Cairo University. After ap-
proval of the study protocol by the Local Ethical Committee
and obtaining fully informed written consent from the nearest
relative to the patient, 70 patients who had sustained a closed
traumatic brain injury requiring intensive care and/or surgical
interference were studied.
Patients with brain death, penetrating injury, infection and
possible diseases that may alter the estimated parameters
especially cerebrovascular accident, spinal injuries or spinal
surgical procedures, Alzheimer or depressive psychosis was
excluded. Twenty volunteers who passed the preliminary test
for blood donation and within cross-matched age and sex were
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for serum levels of estimated markers without undergoing
other investigations conducted in the study.
All patients were admitted to surgical ICU and underwent
clinical evaluation for all traumatized organs using Injury
Severity Score (ISS) [18] and concerning TBI Glasgow Coma
Scale (GCS) [19] was recorded after non-surgical resuscitation.
Then, all underwent CT scanning of the brain and patients
with a surgically treatable mass (subdural or epidural hema-
toma, large contusion with mass effect, and so on) were taken
to the operating room for decompressive craniotomy. Patients
free of hematoma or had minute-to-small hematoma not
necessitating surgical interference were kept under observation
for development of signs of or expansion of already present
intracranial hematoma; and if occurred was assured by fol-
low-up cranial CT.
Medical treatment was conducted according to patients’
condition and consisted of sedation using (midazolam, fenta-
nyl), intubation and ventilation to mild hypocapnia (PaCO2
26–30 mm Hg), and a muscle relaxant was administered if
required.
Patients who had a surgically treatable lesion underwent
ICP monitor insertion intraoperatively. The cerebral perfusion
pressure (mean arterial pressure-intracranial pressure) was
maintained >70 mm Hg with ﬂuids and infusion of norepi-
nephrine if required. Intracranial pressure levels >20 mm Hg
were treated with mannitol, and moderate hyperventilation
(PaCO2 > 35 mm Hg) otherwise, barbiturate coma with burst
suppression was induced. Patients who underwent conserva-
tive treatment were observed clinically and with repeated
CCT on deterioration of neurological status, changes of
GCS or appearance of manifestations of increased ICP.
Venous blood samples were obtained from all enrolled pa-
tients at time of admission and patients who showed deteriora-
tion during conservative treatment gave a second sample for
comparison. Blood samples were allowed to clot then serum
was separated by centrifugation at 3000 rpm for 10 min. Serum
was removed, placed in pyrogen-free Eppendorf tubes and
stored at 80 C until ELISA assayed for estimation of serum
S100 protein, NSE, and GFAP.
3. Statistical analysis
Obtained data were presented as mean ± SD, ranges, numbers
and ratios. Results were analyzed using paired t-test and Chi-
square test. Statistical analysis was conducted using the SPSS
(Version 10, 2002) for Windows statistical package. p value
<0.05 was considered statistically signiﬁcant.4. Results
The study included 70 patients; 52 males and 18 females with
mean age of 40.8 ± 8; range: 22–64 years. There were 43 pa-
tients (61.4%) with CCT documented intracranial hematoma;
21 patients (27.1%) had epidural hematoma, 15 patients
(8.6%) had subdural hematoma and seven patients (4.3%)
had cerebral hematoma; the remaining 27 patients (38.6%)
had CT free of hematoma collection. Twenty-six patients of
those who had hematoma; 12 had epidural hematoma, nine
had subdural hematoma and ﬁve had cerebral hematoma,
underwent surgical hematoma evacuation, while the other 17hematoma patients and the 27 hematoma free patients were
kept under observation at surgical ICU. Throughout the
observation period, 15 patients; 10 with hematoma and ﬁve
of hematoma free developed symptoms of increased ICP and
follow-up CCT examination deﬁned four cases of expanding
hematoma and one case of hematoma free developed hema-
toma and these ﬁve cases underwent surgical evacuation.
Thirty-nine patients (55.7%) responded to conservative treat-
ment and were discharged from the ICU to complete their fol-
low-up at the surgical ward, while a total of 31 patients
(44.3%) had surgical interference and completed their postop-
erative care at ICU. Thus, 15 patients required frequent CCT
for establishment of the diagnosis of surgical intracranial
hematoma in only ﬁve of them with 66.7% rate for unneces-
sary follow-up CCT (Table 1).
Mean ISS score of enrolled patients was 28.3 ± 8.8; range:
17–57 and mean GCS was 9.8 ± 2.6; range: 5–14. Mean ISS
score of patients with intracranial hematoma (30.9 ± 11.2;
range: 17–57) was non-signiﬁcantly (p> 0.05) higher com-
pared to hematoma free patients, (26.6 ± 6.4; range: 17–41),
while had signiﬁcantly (p< 0.05) lower GCS (7.2 ± 1.3;
range: 5–10) compared to hematoma free patients,
(11.5 ± 1.4; range: 9–14).
Mean serum levels of studied parameters were signiﬁcantly
higher in all patients, irrespective of the result of CCT, com-
pared to controls with signiﬁcantly higher levels in patients
had hematoma (positive CCT) compared to those had negative
CCT. Patients required surgical interference had signiﬁcantly
higher serum levels of the three parameters compared to pa-
tients managed conservatively. On contrary, patients who
showed deterioration during conservation showed non-signiﬁ-
cantly higher GFAP, but non-signiﬁcantly lower S100 and
NSE serum levels compared to those responded to conserva-
tive treatment and discharged to the ward. Moreover, serum
levels of the three markers showed non-signiﬁcant difference
between patients with positive follow-up CCT compared to
those with negative follow-up CCT (Table 2).
Patients who showed deterioration during follow-up had
signiﬁcantly higher serum levels of S100 protein and GFAP,
but non-signiﬁcantly higher serum NSE levels compared to
their levels estimated at time of admission. Moreover, patients
with positive follow-up CCT showed signiﬁcantly higher serum
levels of the three parameters compared to their at-admission
levels, while those with negative follow-up CCT showed non-
signiﬁcantly higher levels (Table 3).
The percentage of increase of serum GFAP levels in follow-
up sample obtained from patients with positive follow-up CCT
compared to at-admission levels was signiﬁcantly higher com-
pared to the percentage of increase in serum S100 protein and
NSE with non-signiﬁcant difference in the percentage of in-
crease of S100 protein and NSE (Table 3, Fig. 1). However,
the percentage of change of serum levels of studied parameters
in cases showed deterioration during follow-up showed non-
signiﬁcant serum S100 and NSE levels compared to the change
in serum GFAP levels (Table 3).5. Discussion
Patients had signiﬁcantly elevated serum markers compared to
control group with signiﬁcantly higher levels in patients who
had intracranial hematoma and those who required surgical
Table 1 Patients’ distribution according to CCT results and applied therapeutic modalities.
Management preliminary CCT Surgical evacuation Conservation and follow-up CCT
Total Discharge Deterioration
Positive CCT Negative CCT
Positive 43 26 17 7 4 6
Negative 27 0 27 22 1 4
Total 70 26 44 29 5 (Surgical) 10 (Conservative)
Table 2 Mean (±SD) serum levels of estimated parameters in studied patients distributed according to therapeutic modality and
outcome.
S100 protein (lg/L) NSE (lg/L) GFAP (ng/L)
Control 0.239 ± 0.083 8.4 ± 2.8 1.5 ± 0.37
Preliminary CCT (n = 70)
Positive (n= 43) 0.878 ± 0.377* 23.3 ± 7* 102.9 ± 47.1*
Negative (n= 27) 0.492 ± 0.35 19.4 ± 4.8 66.8 ± 22.4
Therapeutic modality (n = 70)
Surgical (n= 26) 1.01 ± 0.31 24.5 ± 5.8 113.1 ± 46.2
Conservative (n= 44) 0.562 ± 0.37 20.2 ± 6.4 74.8 ± 34.2
Outcome of conservative therapy (n = 44)
Discharge (n= 29) 0.578 ± 0.416 21.2 ± 6.6 69.2 ± 27.2
Deterioration (n= 15) 0.517 ± 0.27 18.2 ± 5.8 86 ± 45.5
Follow-up CT of deteriorated cases (n = 15)
Positive (n= 5) 0.547 ± 0.33 18 ± 4.8 92.2 ± 49.3
Negative (n= 10) 0.525 ± 0.25 17.8 ± 3.9 73.8 ± 31.4
* Signiﬁcance versus patients had negative preliminary CCT.
 Signiﬁcance versus patients received conservative treatment.
Table 3 Mean (±SD) serum levels of estimated parameters in patients showed deterioration during NICU stay and percentage of
change compared to at-admission sample.
S100 protein (lg/L) NSE (lg/L) GFAP (ng/L)
Patients had deterioration (n = 15)
At admission 0.517 ± 0.27 18.2 ± 5.8 86 ± 45.5
At follow-up 0.606 ± 0.29* 19.7 ± 6.6 104.66 ± 55.9*
Patients had positive follow-up CCT (n = 5)
At admission 0.547 ± 0.33 18 ± 4.8 92.2 ± 49.3
At follow-up 0.612 ± 0.35* 20.6 ± 9.4* 122.4 ± 50.4*
% of change 15.5 ± 8.9 15.9 ± 7.3 54.1 ± 25.3
Patients had negative follow-up CCT (n = 10)
At admission 0.525 ± 0.25 17.8 ± 3.9 73.8 ± 31.4
At follow-up 0.603 ± 0.284 20.6 ± 6.4 95.8 ± 29
% of change 14.7 ± 3.8 13.6 ± 12 10.3 ± 4.4
* Signiﬁcance versus at-admission levels.
 Signiﬁcance versus percentage of change in serum levels of S100 protein.
 Signiﬁcance versus percentage of change in serum levels of NSE.
270 H.A. Shehab, Y.H. Nassarinterference compared both to those free of hematoma and to
patients managed conservatively, respectively. This ﬁnding
indicated a fact that TBI is associated with release of these
markers irrespective of the extent of brain trauma, but their
levels increase with increased injury severity.
This ﬁnding indicated a fact that traumatic brain affection
irrespective of the presence of bleeding or not and irrespective
of the extent of trauma and its impact on consciousness results
in injury of brain tissue with concomitant release of thesemarkers and indicating their validity for diagnosis of brain tis-
sue injury and reﬂecting its severity. The obtained data sup-
ported those previously reported in literature concerning the
serum levels of neuromarkers after TBI; Berger et al. [20]
found serum concentrations of S100 protein, NSE and myelin
basic protein obtained at the time of pediatric TBI may be use-
ful in predicting severity and outcome. Vajtr et al. [21] also,
found serum values of NSE and protein S-100 overdrow the
reference value in cases with negative ﬁndings on CT scan,
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Figure 1 Percentage of change of serum levels of studied
parameters estimated at deterioration versus at-admission levels
in patients showed positive follow-up CCT.
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admission day, the mean GFAP level in non-TBI patients sig-
niﬁcantly lower compared with TBI patients and the signiﬁ-
cant difference extended to day 2 after trauma.
Fifteen patients out of 44 patients managed conservatively
showed manifestations of neurological deterioration and esti-
mation of serum markers at time of deterioration detected sig-
niﬁcant increase of serum S100 protein and GFAP with non-
signiﬁcant increase of serum NSE compared to their levels esti-
mated at admission. However, such increase was more mani-
fest in those proved to have increased hematoma size in four
patients and new collection in one patient with previously free
CCT, while no radiological abnormalities were detected in the
other 10 patients and this was conﬁrmed by new frequent
CCT. Thus, CCT could be spared in about 67% of patients
showed deterioration unless they had signiﬁcantly increased
serum neuromarkers. Such ﬁnding goes in hand with Korﬁas
et al. [23] who found serum S100 alteration indicated neurolog-
ical improvement or deterioration and surgical treatment re-
duced S100 levels and concluded that serum S100 protein
reﬂects injury severity and improves prediction of outcome
after severe TBI and may also have a role in assessing the efﬁ-
cacy of treatment after severe TBI.
The reported signiﬁcantly elevated serum NSE in total pa-
tients, with non-signiﬁcant increase in those showed deteriora-
tion points to a fact that no marker could be reliable by itself
only. Another limitation was the non-signiﬁcant elevation of
serum neuromarkers in patients who showed deterioration
and had negative CCT; both limitations indicated the necessity
for the use of combined serum markers so as to cover the pit-
falls of each and the better diagnostic yield of calculation of
the percentage of change in serum levels instead of relying
on the crude serum level. In support of this assumption, the
percentage of change in serum GFAP was signiﬁcantly higher
compared to that calculated for both S100 and NSE in patients
who required surgical interference after deterioration during
conservative treatment, while showed non-signiﬁcantly lower
percentage of change compared to that calculated for both
of S100 and NSE in patients did not require surgical
interference.These ﬁndings could be attributed to the data provided by
Benneker et al. [24] who suggested that S100 serum levels
might be useful for the diagnosis of acute vertebral body and
spinal cord injury with a high negative predictive power espe-
cially if associated with fractured large bones and by Guzel
et al. [25] who reported that there are several serious limita-
tions of the use of NSE as a biomarker in TBI because hypo-
perfusion, extracranial trauma, bleeding, liver, or kidney
damage also increase its level. On contrary, Honda et al. [26]
reported that despite serum GFAP, S100, and NSE levels were
signiﬁcantly higher in TBI patients than in the non-TBI pa-
tients serum GFAP had the largest area under ROC curve
(0.983), with 88.9% sensitivity and 100% speciﬁcity for TBI,
deﬁned by abnormal head CT ﬁndings, in prehospital-triaged
patients with severe trauma. Wiesmann et al. [27] investigated
the predictive value of early serum levels of S100 and GFAP in
TBI and found blood levels of S100 and GFAP indicate the
severity of brain damage and are correlated with neurological
prognosis after trauma.
The better yield of estimation of serum GFAP could be
attributed to its power for differentiation between hemorrhagic
and non-hemorrhagic brain insults; Und et al. [28] found no
differences in S100 and NSE levels between patients with ische-
mic stroke or intracranial hemorrhage; however, GFAP levels
were signiﬁcantly higher in intracranial hemorrhage patients.
Dvorak et al. [29] found between 2 and 6 h of stroke onset, ser-
um GFAP was signiﬁcantly higher in intracranial hemorrhage
patients than in ischemic stroke patients and serum GFAP val-
ues were signiﬁcantly correlated with intracranial hematoma
volume. Also, Lumpkins et al. [22] found at admission day,
the mean GFAP level in non-TBI patients was signiﬁcantly
lower compared to TBI patients and the AUC for GFAP
was 0.90.
These data illustrate the validity of estimation of serum lev-
els of neuromarkers as adjuvant diagnostic and prognostic
tools for closed TBI patients, but serum level of GFAP showed
superior applicability and was more valid prognostic modality
that could spare unnecessary CCT if applied as the percentage
of change in comparison to at admission levels. However,
wider scale studies are required for conﬁrmation of the ob-
tained results and identiﬁcation of cutoff points for differenti-
ation between surgical and non-surgical cases and for
deﬁnition of deterioration.References
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